Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Questcor Pharmaceuticals, Inc. (“Questcor” or the “Company”) (Nasdaq: QCOR) relating to the proposed acquisition by Mallinckrodt plc (“Mallinckrodt”).
Click here to learn more about the investigation http://brodsky-smith.com/742-qcor-questcor-pharmaceuticals-inc.html, or call 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Questcor shareholders will receive only $30.00 in cash and 0.897 shares of Mallinckrodt stock for each share of Questcor stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Questcor for not acting in the Company’s shareholders' best interests in connection with the sale process. The transaction may undervalue Questcor as the Company has reported substantial increases in net sales and an analyst has placed a $99.00 per share price target on Questcor stock.
If you own shares of Questcor common stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at firstname.lastname@example.org, by visiting http://brodsky-smith.com/742-qcor-questcor-pharmaceuticals-inc.html, or calling toll free 877-LEGAL-90.Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.